Henry Schein, Inc. (NASDAQ: HSIC) Sees Positive Analyst Sentiment and Strategic Growth Initiatives

Analysts have raised the consensus price target for Henry Schein, Inc. (NASDAQ: HSIC) to $80.5, with Barclays analyst Steven Valiquette setting a target of $82, reflecting growing optimism. Despite underperformance relative to the S&P 500, Henry Schein is considered a "Buy" due to its attractive valuation and potential for revenue and earnings growth supported by strategic investments and acquisitions. The company's stock has risen 6.5% since its last earnings report, with ongoing share buybacks reducing shares by 32% since 2011, bolstering EPS and providing downside protection.

Henry Schein, Inc. (NASDAQ: HSIC) is a leading global provider of healthcare products and services, primarily serving dental and medical practitioners. The company operates through two main segments: Health Care Distribution, which offers a wide range of dental and medical products, and Technology and Value-Added Services, which provides software and technology solutions to enhance practice management.

The consensus price target for Henry Schein has seen some fluctuations over the past year. Last month, the average price target was $75, which increased to $80.5 in the last quarter. This rise suggests growing optimism among analysts, possibly due to positive developments in the company's operations or market conditions. Analyst Steven Valiquette from Barclays has set a price target of $82, indicating further confidence in the stock's potential.

Despite recent underperformance relative to the S&P 500, Henry Schein is still considered a "Buy" due to its attractive valuation compared to peers. The company's financial results have been mixed, but management's guidance for 2025 indicates potential revenue and earnings growth. This optimism is supported by ongoing acquisitions and a strategic $250 million investment from KKR, which bolsters the company's long-term growth and capital allocation flexibility.

Henry Schein's stock has experienced a 6.5% increase since its last earnings report, released 30 days ago. The company reported solid first-quarter earnings, with full-year earnings per share (EPS) guidance set between $4.80 and $4.94. Analysts project an EPS of $5.27 for 2026. The introduction of new business units and revamped sales incentives aims to boost revenue growth, which has been stagnant since 2022.

Ongoing share buybacks have resulted in a 32% reduction in shares since 2011, supporting EPS and providing downside protection for the stock. As Henry Schein prepares to release its second-quarter 2025 financial results on August 5, 2025, investors should stay updated with the latest company announcements and industry trends that could impact the stock's performance and analysts' price targets.